3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
OTHER_GOV
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Thoracic
3
Conditions
Carcinoma, Non-Small-Cell Lung
79
Lung Neoplasms
44
Carcinoma, Hepatocellular
42
Small Cell Lung Carcinoma
28
Breast Neoplasms
19
Cholangiocarcinoma
17
Urinary Bladder Neoplasms
16
Biliary Tract Neoplasms
15
Neoplasms
13
Liver Neoplasms
13
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
11
Ovarian Neoplasms
10
Carcinoma
10
Squamous Cell Carcinoma of Head and Neck
8
Stomach Neoplasms
7
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Transitional Cell
6
Melanoma
5
Gallbladder Neoplasms
5
Esophageal Neoplasms
5
Carcinoma, Renal Cell
5
Adenocarcinoma Of Esophagus
5
Adenocarcinoma
5
Prostatic Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Neoplasms by Site
4
Mesothelioma
4
Interventions
pembrolizumab
119
Cisplatin
33
lenvatinib
29
Carboplatin
28
Paclitaxel
27
Docetaxel
14
Pemetrexed
13
Fluorouracil
12
Capecitabine
11
Saline Solution
10
Oxaliplatin
10
Gemcitabine
10
Albumin-Bound Paclitaxel
7
olaparib
6
Leucovorin
6
Bevacizumab
6
epacadostat
5
belzutifan
5
Etoposide
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enzalutamide
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Radiotherapy
3
Levoleucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
durvalumab
×
1 year
×
Clear all
NCT04380636
2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
870 enrolled
NCT07192926
2026-02-20
SARCO-CTI
Ankara Etlik City Hospital
Completed
131 enrolled
NCT05298423
2025-08-01
KEYVIBE-006
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
611 enrolled